MedTrace Logo

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

NCT02462954 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-05-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of ContraGel versus the hydroxyethylcellulose (HEC) Universal Placebo gel when used with the Caya diaphragm during two 7-day periods of daily use, the first without intercourse and the second with intercourse.

Conditions

  • Contraception

Interventions

DEVICE

ContraGel

DEVICE

HEC Universal Placebo gel

Sponsors & Collaborators

  • CONRAD

    lead OTHER

Principal Investigators

  • Christine Mauck · CONRAD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462954 on ClinicalTrials.gov